Indaptus Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Multiple entities and individuals associated with Yorkville Advisors have filed a Schedule 13G amendment for Indaptus Therapeutics, reporting zero shares beneficially owned.
NASDAQ
SCHEDULE 13G: Yorkville Advisors Entities Disclose 9.99% Stake in Indaptus Therapeutics via Standby Equity Purchase Agreement
Multiple entities affiliated with Yorkville Advisors Global, including YA II PN, Ltd., have disclosed a 9.99% beneficial ownership stake in Indaptus Therapeutics, Inc., stemming from a Standby Equity Purchase Agreement.